The possibility of preoperative prediction of pathologic complete response in rectal cancer has been studied in order to identify patients who would respond to neoadjuvant therapy and to individualize therapeutic strategies. Endoscopic ultrasound of the rectum is an accurate method for the evaluation of local tumor and lymph node invasion. Objective: To evaluate the potential of endoscopic ultrasound as a predictor of complete pathological response to neoadjuvant treatment in patients with locally advanced rectal cancer. Material and methods: Retrospective study of patients with rectal cancer from January 2014 to December 2016. Results: We obtained a statistical association between T stage by endoscopic ultrasound and complete pathological response (p = 0.015). It is not so for N, sphincter involvement, circumferential involvement and maximum tumor thickness (p = 0.723, p = 0.510, p = 0.233 and p = 0.114, respectively). When multivariate logistic regression analysis was applied to assess the degree of influence of the predictor variables on pathologic response, none of these variables was associated with complete pathologic response. Conclusion: Prediction of pathologic complete response in rectal cancer has been considered as the crucial point upon which treatments for rectal cancer could be individualized. So far, no imaging method has been able to demonstrate efficacy in predicting complete pathologic response, and in turn there is no direct association between any endosonographic finding that can accurately predict it.

Colorectal cancer is the fourth leading cause of death worldwide and the fifth leading cause of cancer death in Colombia. Magnetic resonance imaging is the ideal modality for the evaluation of colorectal cancer, since it allows staging by determining invasion beyond the muscularis propria, extension towards adjacent organs, identification of patients who are candidates for chemotherapy or pre-surgical radiotherapy and planning of the surgical procedure. The key point is based on the differentiation between T2 and T3 stages through the use of sequences with high-resolution T2 information. In addition to this, it allows the assessment of the size and morphology of the lymph nodes, and considerably increases the specificity for the detection of lymph node involvement. MRI is a technique with high specificity and high reproducibility.

Multiple myeloma (MM) is a hematologic cancer characterized by clonal proliferation of plasma cells within the bone marrow. It is the most serious form of plasma cell dyscrasias, whose complications—hypercalcemia, renal failure, anemia, and lytic bone lesions—are severe and justify the therapeutic management. Imaging of bone lesions is a cardinal element in the diagnosis, staging, study of response to therapy, and prognostic evaluation of patients with MM. Historically, the skeletal radiographic workup (SRW), covering the entire axial skeleton, has been used to detect bone lesions. Over time, new imaging techniques that are more powerful than SRW have been evaluated. Low-dose and whole-body computed tomography (CT) supplants SRW for the detection of bone involvement, but is of limited value in assessing therapeutic response. Bone marrow MRI, initially studying the axial pelvic-spinal skeleton and more recently the whole body, is an attractive alternative. Beyond its non-irradiating character, its sensitivity for the detection of marrow damage, its capacity to evaluate the therapeutic response and its prognostic value has been demonstrated. This well-established technique has been incorporated into disease staging systems by many health systems and scientific authorities. Along with positron emission tomography (PET)-18 fluorodeoxyglucose CT, it constitutes the current imaging of choice for MM. This article illustrates the progress of the MRI technique over the past three decades and situates its role in the management of patients with MM.

There are numerous studies reported on the usage of the sapindus emarginatus (SE) fruit in cancer and other treatments in the past few years. In this study, crude SE fruit extract was prepared and it was further used to synthesis gold nanoparticles (Au Nps). The synthesized Au Nps were left embedded in the SE fruit extract. The Au Nps embedded in the SE fruit extract (SE-Au Nps) were characterized using UV-Visiable Spectroscopy, Centrifugal Particle Size analyzer (CPS), Scanning Electron Microscope (SEM) and Fourier Transform Infrared Spectroscopy (FTIR). MTT assay was carried out for both SE fruit extract and SE-Au Nps on MCF7 breast cancer cell line and thus compared. The UV-Visible Absorbance for the SE-Au Nps was obtained at 543 nm. The centrifugal particle size analysis of the Au Nps embedded in SE fruit extract showed the size of the nanoparticles to be widely varying with higher fraction of particles between the size ranges of 15 to 20 nm. The morphology of the Au Nps embedded in SE fruit extract was observed using SEM. The presence of Au Nps in SE fruit extract was confirmed using FTIR. The results of the MTT assay on MCF7 breast cancer cell line proved that the % cell viability was less for SE-Au Nps than that of the SE fruit extract alone. Thus, the antiproliferative activity of the SE fruit extract was significantly enhanced by embedding it with Au Nps and it can be effectively used in therapeutic applications after further studies.

The Cu_2–xSe nanoparticles were synthesized by high temperature pyrolysis, modified with aminated polyethylene glycol in aqueous solution and loaded with compound 2,2′–azobis[2–(2–imidazolin–2–yl)propane] dihydrochloride (AIPH). The obtained nanomaterials can induce photothermal effect and use heat to promote the generation of toxic AIPH radicals under the irradiation of near-infrared laser (808 nm), which can effectively kill cancer cells. A series of in vitro experiments can preliminarily prove that Cu_2–xSe–AIPH nanomaterials have strong photothermal conversion ability, good biocompatibility and anticancer properties.

According to the World Health Organization (WHO), breast cancer is among the most common cancers worldwide. Most of the anticancer agents have been showing a variety of side effects. Recently, bacterial proteins have been investigated as promising anticancer agents. Azurin is a bacterial cupredoxin protein secreted from Pseudomonas aeruginosa and has been reported as a potent multi-targeting anticancer agent, which makes it an appropriate candidate for drug delivery. Azurin may be delivered to cancer cells using different carriers like polymeric micro and nanoparticles. In the present study, azurin was extracted from the bacterial host and loaded into chitosan particles. Then its effect on MCF-7 cell line was investigated. Chitosan-azurin particles were made using the ion gelation method. Results showed that chitosan-azurin particles are about 200 nm, and the loading of the protein in particles did not affect its integrity. The MTT assay showed a significant reduction in cell viability in azurin and chitosan-azurin-treated cells. The toxicity level after 5 days was 63.78% and 82.53% for free azurin and chitosan-azurin-treated cells, respectively. It seems using an appropriate carrier system for anticancer proteins like azurin is a promising tool for developing low side effect anticancer agents.